Tweedy Browne Co LLC Has $3.17 Million Stock Holdings in GSK plc (NYSE:GSK)

Tweedy Browne Co LLC lessened its stake in shares of GSK plc (NYSE:GSK - Free Report) by 13.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 93,816 shares of the pharmaceutical company's stock after selling 14,219 shares during the quarter. Tweedy Browne Co LLC's holdings in GSK were worth $3,173,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. United Bank boosted its position in shares of GSK by 7.3% in the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company's stock valued at $1,054,000 after purchasing an additional 1,760 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of GSK by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company's stock worth $4,971,000 after buying an additional 14,687 shares during the period. CreativeOne Wealth LLC purchased a new position in shares of GSK in the third quarter worth approximately $213,000. Fred Alger Management LLC raised its holdings in shares of GSK by 9.1% during the third quarter. Fred Alger Management LLC now owns 44,801 shares of the pharmaceutical company's stock valued at $1,831,000 after acquiring an additional 3,733 shares during the period. Finally, Atom Investors LP acquired a new stake in shares of GSK during the third quarter valued at approximately $296,000. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.25.

Remove Ads

GSK Stock Performance

GSK stock traded down $0.21 on Wednesday, reaching $37.66. 3,720,028 shares of the stock were exchanged, compared to its average volume of 4,473,291. The stock has a market cap of $77.95 billion, a PE ratio of 23.69, a PEG ratio of 1.12 and a beta of 0.58. The firm has a fifty day moving average price of $37.49 and a two-hundred day moving average price of $36.63. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.18%. GSK's dividend payout ratio (DPR) is presently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.